Cegedim Sa · EURONEXT:ALCGM
Cegedim Sa — H1 2011 Earnings Presentation
35 slides from Cegedim Sa's earnings presentation, September 2011
Slide 1: Cegedim HY'11 Results
Cegedim HY’11Results September, 2011
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking statements involve risk and uncertainty. Forward-looking statements represent the comp
Slide 3: Cegedim profile
Cegedim profile | > Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | Finance 3 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 4: Key figures
Key figures | > Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | Finance 4 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 5: Cegedim activities focus on healthcare
Cegedim activities focus on healthcare | > Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | Finance 5 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 6: No direct competitor covers the entire value chain
No direct competitor covers the entire value chain | > Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | Finance 6 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 7: Snapshot of Cegedim strength
Snapshot of Cegedim strenght | > Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | Finance 7 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 8: CRM & Strategic Data Snapshot
CRM & Strategic Data Snapshot | Group | > CRM & Strategic Data | Healthcare Professionals | Insurance & Services | Finance 8 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 9: Highlights
Highlights Country 2009 2010 2011 2015e Mature 325 000 316 000 301 000 210 000 Emerging 179 000 194 000 219 000 305 000 Other 7 000 8 000 10 000 15 000 Total 511 000 518 000 530 000 530 000 | Group | > CRM & Strategic Data | Healthcare Professionals | Insurance & Services | Finance 9 This document s
Slide 10: An Award Winning Company
An Award Winning Company IDC Ph Pharmaceutical ti l SFA MarketScape M k tS ¼ What IDC Says About Cegedim “Cegedim’s application ranks among the best available for breadth of functionality, user interface and functional flexibility…” “Cegedim offers a complete line of deployment options (on-premise,
Slide 11: Key Wins/Renewals 1st Half 2011
Key Wins/Renewals 1st Half 2011 Top 10 Biopharm Cy Leading Biopharm Cy 3 Emerging Biopharma Cies Global EU US MI SaaS in Emerging markets Migrate to MI for IPad in 15 countries 2 Cy selected MI for Ipad, 1 Cy upgrade to MI Top 10 Pharmaceutical Cy Various Large, Mid-Tier and Germany Emerging Pharma
Slide 12: Healthcare Professionals Snapshot
Healthcare Professionals Snapshot | Group | CRM & Strategic Data | > Healthcare Professionals | Insurance & Services | Finance 12 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 13: Expertise
Expertise | Group | CRM & Strategic Data | > Healthcare Professionals | Insurance & Services | Finance 13 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 14: Global presence
Global presence | Group | CRM & Strategic Data | > Healthcare Professionals | Insurance & Services | Finance 14 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 15: Highlights
Highlights ¼ Cegedim Healthcare Software ¼ Cegelease ¼ Gouvernements initiatives Drop of around 13% in Governments across the globe recognize the importance of integrated healthcare systems C Cegelease’s l ’ revenue Healthcare modernization is one of the priority areas of fund allocation in all
Slide 16: Insurance & Services Snapshot
Insurance & Services Snapshot | Group | CRM & Strategic data | Healthcare professionals | > Insurance & Services | Finance 16 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 17: Expertise
Expertise | Group | CRM & Strategic data | Healthcare professionals | > Insurance & Services | Finance 17 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 18: Highlights
Highlights Industry in turmoil with the online ¼ Cegedim SRH services Robust trend in the sales Cegedim Activ hampered by a of services associated tough year-on-year comparison with outsourcing payroll Rebound expected in the second ¼ Cegedim C di e-business b i half-year 2011 Success in
Slide 19: Finance
Finance 02 19 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 20: HY'11 financial snapshot
HY’11 HY 11 financial snapshot | Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | > Finance 20 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 21: Consolidated revenue in line with targets
Consolidated revenue in line with targets HY’11 sector development in % versus HY 2010 I millions In illi off euros HY 2011 HY 2010 Organic Structure Str ct re Currency C rrenc Reported CRM & Strategic data 249.2 249.1 +0.3% +0.3% ‐0.6% +0.0% Healthcare professionals 140.2 138.7 ‐3.3% 4.3% +0.1% +1.
Slide 22: Well-balanced and diversified revenue mix
Well-balanced and diversified revenue mix Revenue breakdown by Highly diversified operations Low customer concentration as of December 2010 First client: 5% of Group revenue Top 5 client: 15% % off Group G revenue Top 10 client: 22% of Group revnue | Group | CRM & Strategic Data | Healthcare P
Slide 23: HY'11 summarized income statement
HY’11 HY 11 summarized income statement in € millions HY'11 HY'10 Δ Revenue 458.6 448.8 +2.2% Investment in Innovation Capitalized production 22.5 15.2 +48.4% Purchases consumed ‐49.0 ‐48.6 +0.8% Detached personnel External expenses ‐121.6 ‐110.2 +10.3% Taxes ‐7.5 ‐7.1 +5.5% Payroll costs ‐225.8 ‐21
Slide 24: Recurring EBITDA and EBIT per sector
Recurring EBITDA and EBIT per sector EBITDA from continuing operations HY'11 HY'10 HY'11 HY'10 in millions of € in % CRM & Strategic data 20.4 31.3 8.2% 12.6% Healthcare professionals 40.0 39.9 28.5% 28.8% Robust margin Insurance & Services 15.1 13.0 21.8% 21.2% Cegedim 75.4 84.1 16.4% 18.7% EBIT fr
Slide 25: Change in net earnings
Change in net earnings P&L part 2 Net cost of financial debt in € millions HY'11 HY'10 Δ in € millions HY'11 HY'10 EBIT 38.7 45.2 ‐14.4% Interests paid on financial debt ‐16.3 ‐10.9 Net cost of financial debt ‐21.0 ‐21.6 ‐2.5% Valuation of financial instruments ‐3.9 ‐3.0 Income taxes ‐5.0 ‐16.1 ‐68.
Slide 26: HY'11 Summarized balance sheet
HY’11 HY 11 Summarized balance sheet | Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | > Finance 26 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 27: New €280m credit facility
New €280m credit facility Debt structure Debt repayment €340m €80m Undrawn RCF Bank Maturity extension: 66% of total debt has more €200m Term loan € than 4 years maturity Compliance Bond Hedged €80m €300m Bond 86% or fix rate €85m 100% EUR with €20m €40m €40m €20m Shareholder €45m Subordinated debt
Slide 28: A cash flow-generating model
A cash flow-generating flow generating model | Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | > Finance 28 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 29: Cash flow in € millions
Cash flow in € millions | Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | > Finance 29 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 30: Cegedim is confident in its future growth potential
Cegedim g is confident in its future growth potential based on: ¼ Robust sales momentum, signing a significantly higher number of contracts than last year in part du to the return to normal in the roll-out of g CRM offerings ¼ Potential from emerging countries ¼ R&D efforts ¼ The surge in the medica
Slide 31: Higher year-end seasonal effect
Higher year year-end end seasonal effect 52% of EBIT generated in seconddh halflf year Traditionally higher sales of software at the end of the year Spending of remaining operating budget More use of data and market research in Q4 due to reorganization of sales forces forces, organization of n
Slide 32: 2011 Financial outlook
2011 Financial outlook As of September 2011(1) ¼ More cautious about year-end target Growing G i uncertainty t i t in i FFrance and d the th USA with ith respectt to t the th marketing k ti strategies t t i off pharmaceutical companies. Economic conditions in general ¼ Rigorous cost management r
Slide 33: Strong and stable shareholder base
Strong and stable shareholder base Shareholder base as of end of June 2011 Board of directors Corporate governance Compliance with the recommendation of the AFEP AFEP-MEDEF MEDEF code Creation of Audit, Strategy, Nomination and Compensation committees | Group | CRM & Strategic Data | Healthcare
Slide 34: Share ID
Share ID Q3’11 Revenue November 9 | Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | > Finance 34 This document should not be distributed without Cegedim authorization – Copyright 2011
Slide 35: We welcome your questions and comments
it. . w=, cegedim We welcome your questions and comments Jan Eryk UMIASTOWSKI Chief Investment Officer Head of Investor Relations investor.relations@cegedim.com www.cegedim.com/finance TEL: +33 (Q) 1 49 09 33 36